Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
Amphastar Pharmaceuticals Inc
Gross Profit
Amphastar Pharmaceuticals Inc
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Amphastar Pharmaceuticals Inc
NASDAQ:AMPH
|
Gross Profit
$353.8m
|
CAGR 3-Years
35%
|
CAGR 5-Years
27%
|
CAGR 10-Years
15%
|
|
Johnson & Johnson
NYSE:JNJ
|
Gross Profit
$59.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
2%
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Gross Profit
$34.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
16%
|
CAGR 10-Years
11%
|
|
Pfizer Inc
NYSE:PFE
|
Gross Profit
$38.8B
|
CAGR 3-Years
55%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-1%
|
|
Merck & Co Inc
NYSE:MRK
|
Gross Profit
$46B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
Eli Lilly and Co
NYSE:LLY
|
Gross Profit
$28.8B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
See Also
What is Amphastar Pharmaceuticals Inc's Gross Profit?
Gross Profit
353.8m
USD
Based on the financial report for Dec 31, 2023, Amphastar Pharmaceuticals Inc's Gross Profit amounts to 353.8m USD.
What is Amphastar Pharmaceuticals Inc's Gross Profit growth rate?
Gross Profit CAGR 10Y
15%
Over the last year, the Gross Profit growth was 42%. The average annual Gross Profit growth rates for Amphastar Pharmaceuticals Inc have been 35% over the past three years , 27% over the past five years , and 15% over the past ten years .